Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684136 · ClinicalTrials.gov registry record · Phase 4
Suvorexant in Insomnia Co-morbid With Fibromyalgia
A Phase 4 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02684136 is a Phase 4 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 10 participants.
The verdict
NCT02684136, a Phase 4 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will compare sleep, pain and daytime sleepiness/fatigue in people with insomnia co-morbid with fibromyalgia while treated short-term with suvorexant 20 mg versus placebo.
Interventions
- DRUG placebo
- DRUG suvorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2018-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02684136
The ClinicalTrials.gov registry entry for NCT02684136 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02684136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02684136 about?
NCT02684136 is a clinical study titled "Suvorexant in Insomnia Co-morbid With Fibromyalgia". This study will compare sleep, pain and daytime sleepiness/fatigue in people with insomnia co-morbid with fibromyalgia while treated short-term with suvorexant 20 mg versus placebo.
What is the current status of trial NCT02684136?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2016-02-01. Estimated completion is 2018-07-01.
What interventions are being tested in trial NCT02684136?
The interventions under investigation include: placebo (DRUG), suvorexant (DRUG).
Who is sponsoring clinical trial NCT02684136?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.